Asia Pacific Allergy最新文献

{"title":"Does omalizumab increase the risk of malignancy? A retrospective case-control study in a single tertiary hospital.","authors":"Hyun Jee Kim, Suh Young Lee, Sang-Heon Cho, Hye-Ryun Kang","doi":"10.5415/apallergy.0000000000000137","DOIUrl":"10.5415/apallergy.0000000000000137","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"42-43"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932485/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-thymic stromal lymphopoietin monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps (DUBHE): Rationale and design of a multicenter, randomized, double-blind, placebo-controlled study.","authors":"Shen Shen, Mu Xian, Bing Yan, Feng Lan, Chengshuo Wang, Luo Zhang","doi":"10.5415/apallergy.0000000000000135","DOIUrl":"10.5415/apallergy.0000000000000135","url":null,"abstract":"<p><strong>Background: </strong>Chronic rhinosinusitis with nasal polyps (CRSwNP) has a complex pathogenesis and is difficult to treat, which brings a huge economic burden to society. Despite all the progress in the treatment of CRSwNP, some patients with CRSwNP still experience recurrence. Therefore, there is an urgent need to develop novel drugs and treatments for CRSwNP. Thymic stromal lymphopoietin (TSLP) is produced by epithelial cells and mediates type 2 and nontype 2 inflammation through various downstream cellular immune and inflammatory pathways. Anti-TSLP treatment with tezepelumab has been proven to be effective in treating patients with uncontrolled asthma, regardless of their peripheral blood eosinophil levels being low or high. However, there is no relevant research on the usage of anti-TSLP monoclonal antibodies for the treatment of uncontrolled CRSwNP.</p><p><strong>Objective: </strong>This is the first phase Ib/IIa study for subjects with uncontrolled CRSwNP, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of multiple ascending doses (MAD) of anti-TSLP monoclonal antibody.</p><p><strong>Methods: </strong>The DUBHE is a multicenter, randomized, double-blind, placebo-controlled, phase Ib/IIa clinical study. The study will be composed of 3 periods: a screening/run-in period of 4 weeks, a treatment period of 52 weeks (16 weeks of double-blind treatment period +36 weeks of open-label treatment period), and a safety follow-up period of 12 weeks. No more than 113 subjects with uncontrolled CRSwNP will be divided into 4 groups to receive different doses of CM326 or placebo treatments (55 mg every two weeks [Q2W] group, 110 mg Q2W group, 220 mg Q2W group, and 220 mg every four weeks [Q4W] group). Enrolled patients will be stratified by tissue eosinophil count (TEC).</p><p><strong>Results: </strong>The safety of the monoclonal antibody that targets TSLP in uncontrolled CRSwNP and its preliminary efficacy at 16 weeks of treatment.</p><p><strong>Conclusion: </strong>In this study, for the first time, the safety and preliminary efficacy of MAD of CM326 will be verified. The efficacy of CM326 in patients with eosinophilic CRSwNP (TEC ≥55/high power field [HPF]), as well as noneosinophilic CRSwNP (TEC <55/HPF) will be testified.</p><p><strong>Trial registration: </strong>NCT05324137.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"26-31"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers in allergen immunotherapy: Focus on eosinophilic inflammation.","authors":"Chang-Keun Kim, Zak Callaway, Jin-Sung Park, Ruby Pawankar, Takao Fujisawa","doi":"10.5415/apallergy.0000000000000129","DOIUrl":"10.5415/apallergy.0000000000000129","url":null,"abstract":"<p><p>Asthma and allergic rhinitis (AR) are 2 of the most common chronic inflammatory disorders and they appear to be on the rise. Current pharmacotherapy effectively controls symptoms but does not alter the underlying pathophysiology. Allergen immunotherapy (AIT) is an evidence-based therapy for asthma and AR and has been recognized as the only therapeutic method that actually modifies the allergic disease process. There is a lack of objective markers that accurately and reliably reflect the therapeutic benefits of AIT. A biomarker indicating patients that would benefit most from AIT would be invaluable. Eosinophilic inflammation is a cardinal feature of many allergic diseases. Biomarkers that accurately reflect this inflammation are needed to better diagnose, treat, and monitor patients with allergic disorders. This review examines the current literature regarding AIT's effects on eosinophilic inflammation and biomarkers that may be used to determine the extent of these effects.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"32-38"},"PeriodicalIF":1.6,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of allergic sensitization to <i>Platanus occidentalis</i> among adults with allergic rhinitis: A multicenter study.","authors":"Martín Bedolla-Barajas, Javier Domínguez-Morales, Ilse Mariana Loya-Barriga, Angie Bedolla-Pulido, Luis Alfredo Jiménez-Huerta, Jaime Morales-Romero","doi":"10.5415/apallergy.0000000000000127","DOIUrl":"10.5415/apallergy.0000000000000127","url":null,"abstract":"<p><strong>Background: </strong>In the Americas there are few studies that have evaluated the frequency of allergic sensitization to <i>Platanus occidentalis</i> or sycamore pollen in adult patients with allergic rhinitis (AR).</p><p><strong>Objective: </strong>To determine the prevalence of allergic sensitization to <i>P. occidentalis</i> and to identify factors associated with its presentation.</p><p><strong>Methods: </strong>A cross-sectional study was carried out in 3 centers distributed in the northwest, west, and southeast of Mexico. Allergic sensitization to <i>P. occidentalis</i> was determined with a skin prick test. Prevalence and 95% confidence intervals (CI) were estimated.</p><p><strong>Results: </strong>A total of 404 patients were included, women were 233 (57.7%); the age mean was 33.8 ± 12.9 years. The overall prevalence of sensitization to <i>P. occidentalis</i> was 20.8% (95% CI, 17.1%-25.0%); in the northwestern: 15.9% (95% CI, 9.6%-25.1%); in the western: 21.8% (95% CI, 15.4%-29.9%); and in the southeastern: 22.4% (95% CI, 17.1%-38.8%). Multivariate analysis showed to the following allergens as factors associated with sycamore allergic sensitization: tree pollens (OR, 3.19; <i>P</i> = 0.001), weeds (OR, 2.49; <i>P</i> = 0.004), fungi (OR, 1.96; <i>P</i> = 0.014), and dog or cat epitheliums (OR, 1.88; <i>P</i> = 0.018).</p><p><strong>Conclusion: </strong>Allergic sensitization to <i>P. occidentalis</i> pollen in AR patients is not an infrequent event; consequently, we recommend doing the challenge test in all patients with this allergen, especially in those regions where the tree is present.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"14 1","pages":"21-25"},"PeriodicalIF":1.7,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10932483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140118675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Activities and concentration of alpha-1 antitrypsin and cystatin C in serum from patients with house dust mite asthma","authors":"Mailani Dwi Hidayati, F. C. Iswanti, Samsuridjal Djauzi, Sukamto Koesnoe, Mohamad Sadikin","doi":"10.5415/apallergy.0000000000000124","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000124","url":null,"abstract":"Background: The proteolytic activities of house dust mite (HDM) allergens are involved in the pathogenesis of asthma by cleaving T-junction protein complexes, increasing the permeability of airway epithelial cells, and enabling the allergens to reach the interstitial tissue. The human body contains natural protease inhibitors such as alpha-1 antitrypsin (AAT) with antiserine protease activity and cystatin C with anticysteine protease activity. Objective: This study aimed to investigate the behavior of serum AAT and cystatin C levels in patients with HDM-allergic asthma. Methods: Ten individuals with HDM-allergic asthma and 10 healthy volunteers participated in a cross-sectional study. The serum AAT and cystatin C inhibitory activities were measured using enzymatic assays. ELISA was used to determine the serum AAT and cystatin C concentrations. Results: Serum AAT inhibitory activity (P = 0.445; P > 0.05), AAT concentration (P = 0.290; P > 0.05), and cystatin C concentration (P = 0.419; P > 0.05) did not significantly differ between the patient and control groups. However, serum cystatin C inhibitory activity in the asthmatic patient group was significantly higher than in the healthy subjects (P = 0.001; P < 0.05). There was no correlation between AAT inhibitory activity and AAT concentration or between cystatin C inhibitory activity and cystatin C concentration. Conclusion: These findings suggest that serum cystatin C activity is involved in asthma pathogenesis. Additional research is required to address this issue.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"335 7","pages":"158 - 163"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138625852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APAAACI 2023 International Conference: The innovation revolution in allergy, asthma, and immunology","authors":"B. Thong, R. Pawankar","doi":"10.5415/apallergy.0000000000000130","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000130","url":null,"abstract":"","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" 11","pages":"139 - 141"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of nasal irrigation in the treatment of chronic rhinosinusitis","authors":"Ling Jin, K. Fan, Shaoqing Yu","doi":"10.5415/apallergy.0000000000000120","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000120","url":null,"abstract":"Nasal irrigation (NI) for the local treatment of chronic rhinosinusitis (CRS) has some specificity due to the deep anatomical site of the sinuses. The purpose of this review is to help standardize the application of NI in healthcare practice, improve the prevention and treatment of CRS, and facilitate further research on the local treatment of CRS in the future. We searched the PubMed database for 342 articles in the last decade, using the keywords “saline nasal irrigation” and “chronic rhinosinusitis.” We summarize the studies on the mechanism of action, rinsing solution, rinsing apparatus, and rinsing method of NI for CRS. NI plays an important role in the treatment of CRS, and it is a beneficial low-risk treatment. Isotonic saline is the most accepted flushing solution, and large-volume low-pressure flushing bottles are the flushing devices with the best flushing effect and are generally tolerated by patients. Phage, colloidal silver, and hydrogen can be further studied as components of rinses. NI plays an important role in the treatment of CRS, and it is a beneficial low-risk treatment. Further high-quality and expanded sample size studies on other flushing solutions, flushing head position, flushing frequency, and treatment courses are still needed, and lessons learned in practice.","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":" 35","pages":"187 - 198"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138616308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A case of white bean allergy.","authors":"Teruaki Matsui, Nayu Sato, Masashi Nakamura, Yukiko Iwawaki, Katsumasa Kitamura, Yoshihiro Takasato, Shiro Sugiura, Kayoko Matsunaga, Komei Ito","doi":"10.5415/apallergy.0000000000000111","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000111","url":null,"abstract":"<p><p>White bean allergy is uncommon and rarely reported. Herein, we report a case of white bean allergy in a patient with Down syndrome. A 7-year-old girl with Down syndrome experienced allergic symptoms twice after eating white bean and visited our hospital for a food allergy investigation. An ImmunoCAP assay revealed a white bean-specific IgE (13.4 kU_A/L) in the patient's serum. In addition, her skin prick test result was positive. Moreover, ingestion of 2 g of boiled white beans in an oral food challenge test induced intermittent cough, desaturation, generalized urticaria, abnormal sleep, and mild hypotension. Thus, we diagnosed the patient with white bean allergy. We performed western blotting and mass spectrometric analysis and detected the following allergens: Phytohemagglutinin, group 3 late embryogenesis abundant protein, lipoxygenase, and legumin. In addition, we detected several candidate allergenic proteins for the first time. White bean, runner bean, or azuki bean was considered the primary source of sensitization because although immunoblotting inhibition tests revealed that the abovementioned beans inhibited other legumes, soybean, which she tolerates, showed little inhibition of the other legumes. However, we could not confirm whether the patient could ingest legumes other than soybean or white bean because her family did not wish to continue with further testing. This is the first report of a case of systemic allergic reactions to white bean in a child with Down syndrome. Further studies are needed to identify white bean allergens and understand the relationship between Down syndrome and white bean allergy.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 4","pages":"201-204"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preprandial food-dependent exercise-induced anaphylaxis to banana.","authors":"Thatchai Kampitak","doi":"10.5415/apallergy.0000000000000113","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000113","url":null,"abstract":"<p><p>Food-dependent exercise-induced anaphylaxis is a disorder in which a reaction develops only in association with physical exertion that generally takes place postprandially. The reaction that occurs following food intake after exercise is uncommon. Banana is an infrequent cause of anaphylaxis, which has been previously reported in combination with postprandial exercise in only 1 patient. A probable case of preprandial food-dependent exercise-induced anaphylaxis to banana is described herein together with a brief review of recent related literature.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 4","pages":"199-200"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715744/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"APAAACI clinical pathway on direct provocation testing for penicillin allergy delabeling.","authors":"Philip Hei Li, Bernard Yu-Hor Thong, Ruby Pawankar, Chandima Jeewandara, Rommel Crisenio M Lobo, Hye-Ryun Kang, Padukudru Anand Mahesh, Juan Meng, Sonomjamts Munkhbayarlakh, Duy Le Pham, Ticha Rerkpattanapipat, Min-Moon Tang, Masao Yamaguchi, Amir Hamzah Abdul Latiff, Iris Rengganis, Jiu-Yao Wang, Luo Zhang, Michaela Lucas","doi":"10.5415/apallergy.0000000000000122","DOIUrl":"https://doi.org/10.5415/apallergy.0000000000000122","url":null,"abstract":"<p><strong>Background: </strong>Allergy to penicillin is commonly reported in many countries and is an overwhelming global public health concern. Penicillin allergy labels can lead to the use of less effective antibiotics and can be associated with antimicrobial resistance. Appropriate assessment of suspected penicillin allergy (often including skin testing, followed by drug provocation testing [DPT] performed by allergists) can prevent the unnecessary restriction of penicillin or delabelling. Many countries in the Asia Pacific (AP) have very limited access to allergy services, and there are significant disparities in the methods of evaluating penicillin allergy. Therefore, a clinical pathway for the management of penicillin allergy is essential.</p><p><strong>Objectives: </strong>To develop a risk-stratified clinical pathway for delabeling penicillin allergy, taking into account the distinct epidemiology, patient/sensitization profiles, and disparities of allergy services or facilities within the AP.</p><p><strong>Methods: </strong>A risk-stratified penicillin allergy delabeling clinical pathway was formulated by the Drug Allergy Committee of the Asia Pacific Association of Allergy, Asthma and Clinical Immunology. and members of the Penicillin Allergy Disparities survey in AP each representing one country/region of the AP. The clinical pathway was tested based on a database of anonymized patients who were sequentially referred for and completed penicillin allergy evaluation in Hong Kong.</p><p><strong>Results: </strong>The clinical pathway was piloted employing a \"hub-and-spoke\" approach to foster multidisciplinary collaboration between allergists and nonallergists. A simulation run of the algorithm on a retrospective Hong Kong cohort of 439 patients was performed. Overall, 367 (84%) of patients were suitable for direct DPT and reduced the need for skin testing or specialist's care for 357 (97%) skin test-negative individuals. Out of the skin test-negative patients, 345 (94%) patients had a negative DPT.</p><p><strong>Conclusions: </strong>This risk-stratification strategy for direct oral DPT can reduce the need for unnecessary skin testing in patients with low-risk penicillin allergy histories. The hub and spoke model of care may be considered for further piloting and validation in other AP populations that lack adequately trained allergists.</p>","PeriodicalId":8488,"journal":{"name":"Asia Pacific Allergy","volume":"13 4","pages":"142-147"},"PeriodicalIF":1.7,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10715740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138795520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}